Key Insights

Highlights

Success Rate

95% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

3.3%

2 terminated out of 60 trials

Success Rate

94.6%

+8.1% vs benchmark

Late-Stage Pipeline

25%

15 trials in Phase 3/4

Results Transparency

14%

5 of 35 completed with results

Key Signals

5 with results95% success

Data Visualizations

Phase Distribution

39Total
Not Applicable (14)
P 1 (3)
P 2 (7)
P 3 (8)
P 4 (7)

Trial Status

Completed35
Recruiting9
Unknown7
Not Yet Recruiting5
Terminated2
Active Not Recruiting1

Trial Success Rate

94.6%

Benchmark: 86.5%

Based on 35 completed trials

Clinical Trials (60)

Showing 20 of 20 trials
NCT07563439Phase 2Not Yet RecruitingPrimary

PollenVax Subcutaneous Immunotherapy for Mugwort Pollen-Induced Allergic Rhinitis

NCT07556393Phase 2Completed

Environmental Exposure Unit Trial in Subjects With Ragweed-induced Allergic Rhinitis

NCT06661252Completed

Evaluation of Nasal Biomarkers for Objective Assessment of Disease Severity in Respiratory Disorders

NCT07283250Completed

Development and Validation of the Air Quality Awareness Scale (AQAS) for Parents

NCT07427576Completed

Retrospective Study Evaluating the Effectiveness and Safety of Immunotherapy With Clustoid Max Forte

NCT05720455Phase 4CompletedPrimary

Study to Assess Safety and Efficacy of Fexofenadine Hydrochloride (HCL) + Pseudoephedrine HCL Fixed Dose Combination in Indian Male and Female Participants With Allergic Rhinitis (AR) Who Are 12 Years and Above

NCT06139185CompletedPrimary

The ARHINASD (Allergic Rhinitis in Pediatric Subjects With Nasal Septum Deviation) Project

NCT06858137Not ApplicableCompletedPrimary

Thread Embedding Acupuncture For Rhinitis Allergy

NCT06436534Not ApplicableRecruitingPrimary

Efficacy and Safety of Ganciclovir Capsules in the Treatment of Refractory Moderate-to-severe Allergic Rhinitis

NCT04435990Phase 3RecruitingPrimary

Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites

NCT04898283Phase 3RecruitingPrimary

Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses.

NCT04891237Phase 3RecruitingPrimary

Efficacy and Safety Evaluation for the Treatment of Allergy Against Grass and Olive Pollen

NCT05448066Not ApplicableRecruiting

Molecular Allergen Component Resolved Diagnosis to Decide Immunotherapy

NCT05177744Completed

Toxicity of Micro and Nano Plastics Combined With Environmental Contaminants on the Risk of Allergic Disease

NCT06890572Not ApplicableRecruitingPrimary

Validation of the Efficacy of Air Purifiers in Indoor Environment and Allergic Symptoms in Allergic Rhinitis Patients

NCT05922176RecruitingPrimary

Biomarker Screening for Immunotherapy Response Evaluation Using Microneedle Patch in Patients with Allergic Rhinitis

NCT06741800Not Yet RecruitingPrimary

Microbial Study of Sublingual Immunotherapy Tablets in Patients With Allergic Rhinitis

NCT06741787Not Yet RecruitingPrimary

Microbial Study of Sublingual Immunotherapy Spray in Patients With Allergic Rhinitis

NCT06427577Not ApplicableRecruitingPrimary

Study on the Mechanism of ZhenQiFuZheng in the Treatment of Allergic Rhinitis Based on Intestinal Flora and Metabolites

NCT05122143Not ApplicableCompleted

Efficacy and Safety of AM-301 on Allergic Symptoms of Perennial Allergic Rhinitis Sufferers

Scroll to load more

Research Network

Activity Timeline